Abstract
Abstract
Background
Comprehensive breast cancer risk prediction models enable identifying and targeting women at high-risk, while reducing interventions in those at low-risk. Breast cancer risk prediction models used in clinical practice have low discriminatory accuracy (0.53–0.64). Machine learning (ML) offers an alternative approach to standard prediction modeling that may address current limitations and improve accuracy of those tools. The purpose of this study was to compare the discriminatory accuracy of ML-based estimates against a pair of established methods—the Breast Cancer Risk Assessment Tool (BCRAT) and Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) models.
Methods
We quantified and compared the performance of eight different ML methods to the performance of BCRAT and BOADICEA using eight simulated datasets and two retrospective samples: a random population-based sample of U.S. breast cancer patients and their cancer-free female relatives (N = 1143), and a clinical sample of Swiss breast cancer patients and cancer-free women seeking genetic evaluation and/or testing (N = 2481).
Results
Predictive accuracy (AU-ROC curve) reached 88.28% using ML-Adaptive Boosting and 88.89% using ML-random forest versus 62.40% with BCRAT for the U.S. population-based sample. Predictive accuracy reached 90.17% using ML-adaptive boosting and 89.32% using ML-Markov chain Monte Carlo generalized linear mixed model versus 59.31% with BOADICEA for the Swiss clinic-based sample.
Conclusions
There was a striking improvement in the accuracy of classification of women with and without breast cancer achieved with ML algorithms compared to the state-of-the-art model-based approaches. High-accuracy prediction techniques are important in personalized medicine because they facilitate stratification of prevention strategies and individualized clinical management.
Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(10):727–37 w237–42.
2. Arie S. Switzerland debates dismantling its breast cancer screening programme. BMJ. 2014;348.
https://www.bmj.com/content/348/bmj.g1625.ful
.
3. Christine Bouchardy PP, Lorez M, Clough-Gorr K, Bordoni A, the NICER Working Group. Trends in Breast Cancer Survival in Switzerland. NICER. Zurich: Schweizer Krebsbulletin(Nr. 4/2011); 2011.
4. Mainiero MB, Moy L, Baron P, Didwania AD, diFlorio RM, Green ED, et al. ACR Appropriateness Criteria((R)) breast cancer screening. J Am Coll Radiol. 2017;14(11s):S383–s90.
5. Qin X, Tangka FK, Guy GP Jr, Howard DH. Mammography rates after the 2009 revision to the United States Preventive Services Task Force breast cancer screening recommendation. Cancer Causes Control. 2017;28(1):41–8.
Cited by
84 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献